Skip to main content
    P

    Protalix Biotherapeutics Inc (PLX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $3.02
    -0.03 (-0.98%)

    Market Cap: $257.17M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Protalix Biotherapeutics Inc (PLX) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Protalix Biotherapeutics (PLX) to earn $0.29 per share in the fiscal year ending Dec 31, 2026, on revenue of $87.25M. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is $0.11.

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus falls 62.1% and revenue estimates fall 18.7%.

    Fiscal year ending Dec 31, 2026
    $0.29
    EPS consensus, revenue $87.25M
    Fiscal year ending Dec 31, 2027
    $0.11
    EPS consensus, revenue $70.95M
    Next report
    Mar 16, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.29$0.29 to $0.291$87.25M$82.73M to $91.77M2
    Dec 31, 2027$0.11$0.11 to $0.111$70.95M$69.22M to $72.68M2

    Quarterly Estimates

    The EPS consensus rises from -$0.02 for the quarter ending Dec 31, 2026 to $0.01 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.02-$0.04 to $0.013$12.98M$9.31M to $17.01M3
    Mar 31, 2027$0.01$0.01 to $0.011N/AN/A0

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 3 upward and 1 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202620
    Fiscal year ending Dec 31, 202711
    Quarter ending Mar 31, 202700

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 52.6% from $0.19.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$0.29$0.24$0.24$0.24$0.19+52.6%
    Fiscal year ending Dec 31, 2027$0.11$0.05$0.05$0.05$0.06+100.0%
    Quarter ending Mar 31, 2027$0.01$0.01$0.01$0.01$0.010.0%

    Frequently Asked Questions About PLX

    What is the PLX stock forecast?

    Consensus analyst estimates put Protalix Biotherapeutics's EPS at $0.29 for the fiscal year ending Dec 31, 2026, on revenue of $87.25M.

    What EPS do analysts expect from PLX next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.29, with estimates from $0.29 to $0.29 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.11, with estimates from $0.11 to $0.11 from 1 analyst.

    What revenue do analysts expect from Protalix Biotherapeutics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $87.25M, with estimates from $82.73M to $91.77M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $70.95M, with estimates from $69.22M to $72.68M.

    How many analysts cover PLX?

    1 analyst estimates EPS for Protalix Biotherapeutics for the fiscal year ending Dec 31, 2026.